Day 1 :
Time : 10:00-10:40
Dilip Ghosh has received his PhD from India. He is an international speaker, facilitator and author and professionally associated with Nutriconnect, Australia; Honorary Ambassador, Global Harmonization Initiatives (GHI). He is a fellow of American College of Nutrition (ACN), professional member of Australian Institute of Food Science & Technology (AIFST), an advisor and executive board member of Health Foods and Dietary Supplements Association (HADSA), India and also in editorial board of several journals.
Dilip Ghosh has published more than 90 papers in peer reviewed journals, numerous articles in food and nutrition magazines and books. His most recent book, “Pharmaceuticals to Nutraceuticals: A shift in disease prevention” under CRC Press, USA has been published in 2016.
It is generally accepted worldwide that modern pharmaceuticals will remain out of reach of many people and “health for all” may only be materialized by the use of adequately assessed nutraceutical or phytomedicinal products. The human has been using food bioactive and/or herbal medicine for healing purpose from the beginning of human civilization. In recent times, use of herbal medicine for healthcare has increased steadily all over the world although it was neglected for decades by Western societies. However, the gaps in relation to the safety, claimed efficacy, and quality of herbal products used as herbal medicine, nutraceuticals, health foods, and cosmetics are being realized and addressed by many companies in their product development framework. The combination therapy of the pharmaceuticals and food bioactives in disease prevention and treatments is one of the most discussed topics in recent time.
The transition of the pharmaceutical industry from its traditional business model is ongoing and interesting to see how their next blockbuster molecule could be derived through different routes. It is proposed that the industry is challenged with three interrelated tipping points referring to what the industry sells (service models vs. therapies), to whom (mass markets vs. niche), and how it should organize itself (making connections vs. integration). The transition from current ‘high-risk, high-margin’ business model to ‘low cost high volume’ nutra business model is dependent on many factors and also advised to move into less regulated markets like animal and consumer health.
This presentation will cover:
- Paradigm Shift in Healthcare Industry: From Pharma to nutra
- Change of consumer focus: From illness to wellness
- Peripheral opportunities are also exist for managing chronic lifestyle diseases and ailments
- Combination therapy of pharmaceuticals and food bioactive in disease prevention and treatments
- “Health for all” target is only possible by the use of adequately assessed nutraceutical/phytomedicinal products.
German University in Cairo, Egypt
Time : 10:40-11:20
Ashraf Abadi has completed his PhD from the College of Pharmacy, University of Florida, USA and Cairo University. He is the head of Pharmaceutical Chemsitry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo and former Dean of the Faculty. He has published more than 80 papers in reputed journals and 7 patents and has been serving as an editorial board member and reviewer of reputed international pharmaceutical sciences journals. He supervised more than 6- Master and Ph.D. theses in the field of Drug Discovery and Pharmaceutical Chemistry.
Phosphodiesterase 5 inhibitors are mainly indicated for the treatment of erectile dysfunction. Currently approved compounds differ mainly in their pharmacokinetics profile and propensity to induce side effects caused due to cross inhibition of other PDEs. The mechanism of action of PDE5 inhibitors includes elevating the levels of the universal messenger cGMP in different cells, thus several potential uses and indications are currently emerging including, treatment of pulmonary arterial hypertension, congestive heart failure, Raynaud’s disease, benign prostatic hyperplasia, enhancement of cognitive functions, enhancement of hearing, as well as prevention and treatment of different types of cancer, particularly the colorectal one.
From discovery perspective, a newly emerging class is GAF domain rather than catalytic domain is also emerging. This class shows favorable properties better than classic inhibitors.
ITS College of Pharmacy, India
Time : 11:40-12:20
Presently, S Sadish Kumar is the Director of I.T.S College of Phamacy, Ghaziabad, India. He has been working as a Professor since 2010. He has over 2 decades of Research and Teaching experience.
He is a member of various professional bodies including Royal Society of Chemistry (RSC), UK. He has published 2 books, 30 research articles & presented research papers at conferences held in South Korea, USA, Germany & Egypt and guided over 30 MPharm research projects in Marine and other natural products, guiding PhD projects as well.
His biography has been cited in Marquis Who’s Who in Medicine & Healthcare. He has been selected and commemorated for International Einstein Award for Scientific achievement, International Health Professional of the year to mention a few. His research thirst on Marine algae is widely noted.
For the past few decades, compounds from Marine algae have been gaining importance due to the vast chemical diversity. In our continuous research on algae, scientific data and traditional claims prompted us to investigate on the brown alga Turbinaria ornata (Family: Sargassaceae). The Cyclohexane, Ethyl acetate and Methanolic extracts of Turbinaria ornata were subjected to wide pharmacological screening. Among the extracts, Cyclohexane exhibited cholinomimetic activity by inhibiting the Cholinesterase significantly at P<0.01 in the presence of acetyl choline, Ethyl acetate extract possessed antifungal activity with the MIC of 500 mcg/mL concentration and Methanolic extract showed the highest in vitro DPPH free radical scavenging activity (70.78%) which was comparable to Ascorbic acid, a positive control (78.16%). Also it showed significant anti diabetic activity against Streptozotocin and anti obesity activity against Atorvastatin (P<0.001).